scholarly journals The Added Benefit of Hybrid SPECT/CT in the Diagnosis of Bone Metastasis in Patients with Breast Cancer

2015 ◽  
Vol 17 (1) ◽  
pp. 38-49
Author(s):  
Nasim Khan ◽  
SM Moinul Islam ◽  
Abrar Al Sakib ◽  
Saiyeeda Mahmood ◽  
Gazi Abul Hossian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Nuclear Medicine ◽  
Breast Carcinoma ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Whole Body ◽  
Emission Computed Tomography ◽  
Breast Cancer Patients ◽  
Medicine Physician

The purpose of this study was to investigate the additional benefit of single photon emission computed tomography/computed tomography (SPECT/CT) over whole-body planar bone scintigraphy (planar BS) and SPECT for the detection of bone metastases in breast cancer patients. Materials & methods: Of 112 consecutively examined patients with histologically confirmed breast carcinoma who underwent bone scintigraphy, 39 required further evaluation by SPECT/CT (n= 23) and SPECT alone (n = 16) because a definite diagnosis could not be established using whole body planar BS alone. The 23 SPECT/CT studies were retrospectively evaluated by two nuclear medicine physicians for planar BS and SPECT images, and one nuclear medicine physician and one radiologist for SPECT/CT on consensus. Each focus of abnormal tracer uptake was recorded for differentiating malignant from benign bone lesions. Clinical and imaging follow-up were used as a reference standard. Results: A total of 72 lesions were evaluated in 23 patients examined by three types of imaging modalities. In 57 of the 72 evaluated lesions, the results of planar BS, SPECT and SPECT/CT were concordant; 52 of the 57 lesions were interpreted as malignant and 5 lesions as benign by all modalities. In 15 of the 72 lesions, consensus reading of fused SPECT/CT images changed the image interpretation of 15 planar BS scans and 9 of the 15 SPECT scans: 7 lesions previously interpreted as benign (on both planar BS and SPECT) were re-classified as malignant and 8 lesions (8 by planar BS and 2/8 by SPECT) previously interpreted as malignant were reevaluated as benign. The highest diagnostic gain was in the thoracolumbar spine, thoracic cage & pelvis. The overall accuracy of SPECT/CT was significantly higher on a lesion-based analysis than planar BS and SPECT (100%vs 79%, p < 0.0001 and 100% vs 83%, p = 0.003). Compared to planar BS and SPECT, the results of SPECT/CT changed diagnosis or treatment in 5/23 patients (21.7%). 39 Conclusion: The hybrid imaging system with SPECT/CT is a feasible technique yielding coregistered dual-modality images. The addition of SPECT/CT improves the diagnostic accuracy for the correct interpretation of bony lesions in breast cancer patients undergoing bone scanning for metastases. SPECT/CT should be routinely used in the work up of postoperative breast carcinoma patients with simultaneous CT evaluation to identify metastatic lesions not detected on bone scintigraphy. DOI: http://dx.doi.org/10.3329/bjnm.v17i1.22490 Bangladesh J. Nuclear Med. 17(1): 38-49, January 2014

scholarly journals Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients

2021 ◽  
Author(s):  
Nils Martin Bruckmann ◽  
Julian Kirchner ◽  
Lale Umutlu ◽  
Wolfgang Peter Fendler ◽  
Robert Seifert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Primary Breast Cancer ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Initial Staging

Abstract Objectives To compare the diagnostic performance of [18F]FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Material and methods A cohort of 154 therapy-naive patients with newly diagnosed, histopathologically proven breast cancer was enrolled in this study prospectively. All patients underwent a whole-body [18F]FDG PET/MRI, computed tomography (CT) scan, and a bone scintigraphy prior to therapy. All datasets were evaluated regarding the presence of bone metastases. McNemar χ2 test was performed to compare sensitivity and specificity between the modalities. Results Forty-one bone metastases were present in 7/154 patients (4.5%). Both [18F]FDG PET/MRI and MRI alone were able to detect all of the patients with histopathologically proven bone metastases (sensitivity 100%; specificity 100%) and did not miss any of the 41 malignant lesions (sensitivity 100%). CT detected 5/7 patients (sensitivity 71.4%; specificity 98.6%) and 23/41 lesions (sensitivity 56.1%). Bone scintigraphy detected only 2/7 patients (sensitivity 28.6%) and 15/41 lesions (sensitivity 36.6%). Furthermore, CT and scintigraphy led to false-positive findings of bone metastases in 2 patients and in 1 patient, respectively. The sensitivity of PET/MRI and MRI alone was significantly better compared with CT (p < 0.01, difference 43.9%) and bone scintigraphy (p < 0.01, difference 63.4%). Conclusion [18F]FDG PET/MRI and MRI are significantly better than CT or bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. Both CT and bone scintigraphy show a substantially limited sensitivity in detection of bone metastases. Key Points • [18F]FDG PET/MRI and MRI alone are significantly superior to CT and bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. • Radiation-free whole-body MRI might serve as modality of choice in detection of bone metastases in breast cancer patients.

scholarly journals Standardized Uptake Value from Semiquantitative Bone Single-Photon Emission Computed Tomography/Computed Tomography in Normal Thoracic and Lumbar Vertebrae of Breast Cancer Patients

2020 ◽  
Vol 14 (5) ◽  
pp. 629-638
Author(s):  
Mohd Fazrin Mohd Rohani ◽  
Siti Nurshahirah Mohd Yonan ◽  
Nashrulhaq Tagiling ◽  
Wan Mohd Nazlee Wan Zainon ◽  
Yusri Udin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Cancer Patients ◽  
Single Photon ◽  
Photon Emission ◽  
Standardized Uptake Value ◽  
Emission Computed Tomography ◽  
Breast Cancer Patients ◽  
Single Photon Emission Computed ◽  
Photon Emission Computed Tomography

Study DesignRetrospective study.PurposeThis study aims to semiquantitatively evaluate the standardized uptake value (SUV) of 99mTc-methylene diphosphonate (MDP) radionuclide tracer in the normal vertebrae of breast cancer patients using an integrated single-photon emission computed tomography (SPECT)/computed tomography (CT) scanner.Overview of LiteratureMolecular imaging techniques using gamma cameras and stand-alone SPECT have traditionally been utilized to evaluate metastatic bone diseases. However, these methods lack quantitative analysis capabilities, impeding accurate uptake characterization.MethodsA total of 30 randomly selected female breast cancer patients were enrolled in this study. The SUV mean (SUVmean) and SUV maximum (SUVmax) values for 286 normal vertebrae at the thoracic and lumbar levels were calculated based on the patients’ body weight (BW), body surface area (BSA), and lean body mass (LBM). Additionally, 106 degenerative joint disease (DJD) lesions of the spine were also characterized, and both their BW SUVmean and SUVmax values were obtained. A receiver operating characteristic (ROC) curve analysis was then performed to determine the cutoff value of SUV for differentiating DJD from normal vertebrae.ResultsThe mean±standard deviations for the SUVmean and SUVmax in the normal vertebrae displayed a relatively wide variability: 3.92±0.27 and 6.51±0.72 for BW, 1.05±0.07 and 1.75±0.17 for BSA, and 2.70±0.19 and 4.50±0.44 for LBM, respectively. Generally, the SUVmean had a lower coefficient of variation than the SUVmax. For DJD, the mean±standard deviation for the BW SUVmean and SUVmax was 5.26±3.24 and 7.50±4.34, respectively. Based on the ROC curve, no optimal cutoff value was found to differentiate DJD from normal vertebrae.ConclusionsIn this study, the SUV of 99mTc-MDP was successfully determined using SPECT/CT. This research provides an approach that could potentially aid in the clinical quantification of radionuclide uptake in normal vertebrae for the management of breast cancer patients.

scholarly journals Germline TP53 Testing in Breast Cancers: Why, When and How?

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3762
Author(s):  
D. Gareth Evans ◽  
Emma R. Woodward ◽  
Svetlana Bajalica-Lagercrantz ◽  
Carla Oliveira ◽  
Thierry Frebourg
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Cancer Patients ◽  
Ductal Carcinoma ◽  
Invasive Breast Carcinoma ◽  
Whole Body ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Degree Relative ◽  
Phyllode Tumour

Germline TP53 variants represent a main genetic cause of breast cancers before 31 years of age. Development of cancer multi-gene panels has resulted in an exponential increase of germline TP53 testing in breast cancer patients. Interpretation of TP53 variants, which are mostly missense, is complex and requires excluding clonal haematopoiesis and circulating tumour DNA. In breast cancer patients harbouring germline disease-causing TP53 variants, radiotherapy contributing to the development of subsequent tumours should be, if possible, avoided and, within families, annual follow-up including whole-body MRI should be offered to carriers. We consider that, in breast cancer patients, germline TP53 testing should be performed before treatment and offered systematically only to patients with: (i) invasive breast carcinoma or ductal carcinoma in situ (DCIS) before 31; or (ii) bilateral or multifocal or HER2+ invasive breast carcinoma/DCIS or phyllode tumour before 36; or (iii) invasive breast carcinoma before 46 and another TP53 core tumour (breast cancer, soft-tissue sarcoma, osteosarcoma, central nervous system tumour, adrenocortical carcinoma); or (iv) invasive breast carcinoma before 46 and one first- or second-degree relative with a TP53 core tumour before 56. In contrast, women presenting with breast cancer after 46, without suggestive personal or familial history, should not be tested for TP53.

scholarly journals The potential role of SPECT/CT in the preoperative detection of sentinel lymph nodes in breast cancer

2011 ◽  
Vol 152 (17) ◽  
pp. 678-688 ◽  
Author(s):  
Zoltán Mátrai ◽  
László Tóth ◽  
Toshiaki Saeki ◽  
István Sinkovics ◽  
Mária Gődény ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Sentinel Lymph Nodes ◽  
Lymph Node Status ◽  
Emission Computed Tomography ◽  
Breast Cancer Patients

Regional lymph node status is the most important prognostic factor in breast cancer. Sentinel lymph node biopsy is the standard method of axillary staging in early breast cancer patients with clinically negative nodes. Preoperative lymphoscintigraphy might support refining biopsy findings by determining the number and location of sentinel lymph nodes. In aged or overweight patients, in the presence of atypical or extra-axillary lymphatic drainage, non-visualized lymph nodes, or sentinel lymph nodes close to the isotope injection site, detection could be aided by a new, hybrid imaging tool: the single-photon emission computed tomography combined with computed tomography (3D SPECT/CT). For the first time in Hungarian language, authors overview the literature: all 14 English-language articles on the implementation of 3D SPECT/CT in sentinel lymph node detection in breast cancer are included. It is concluded that 3D SPECT/CT increases the success rate and quality of preoperative sentinel node identification, and is capable of providing a more accurate staging of breast cancer patients in routine clinical practice. Orv. Hetil., 2011, 152, 678–688.

scholarly journals Lesion-Based Bone Metastasis Detection in Chest Bone Scintigraphy Images of Prostate Cancer Patients Using Pre-Train, Negative Mining, and Deep Learning

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 518
Author(s):  
Da-Chuan Cheng ◽  
Te-Chun Hsieh ◽  
Kuo-Yang Yen ◽  
Chia-Hung Kao
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Deep Learning ◽  
Bone Metastasis ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Breast Cancer Patients ◽  
Location Detection ◽  
The Mean ◽  
Mean Sensitivity

This study aimed to explore efficient ways to diagnose bone metastasis early using bone scintigraphy images through negative mining, pre-training, the convolutional neural network, and deep learning. We studied 205 prostate cancer patients and 371 breast cancer patients and used bone scintigraphy data from breast cancer patients to pre-train a YOLO v4 with a false-positive reduction strategy. With the pre-trained model, transferred learning was applied to prostate cancer patients to build a model to detect and identify metastasis locations using bone scintigraphy. Ten-fold cross validation was conducted. The mean sensitivity and precision rates for bone metastasis location detection and classification (lesion-based) in the chests of prostate patients were 0.72 ± 0.04 and 0.90 ± 0.04, respectively. The mean sensitivity and specificity rates for bone metastasis classification (patient-based) in the chests of prostate patients were 0.94 ± 0.09 and 0.92 ± 0.09, respectively. The developed system has the potential to provide pre-diagnostic reports to aid in physicians’ final decisions.

Sign in / Sign up

Export Citation Format

Share Document